Lutein and zeaxanthin: where the 10:2 ratio comes from

Almost every eye supplement in India states lutein 10 mg and zeaxanthin 2 mg, and almost nobody selling one can say where those numbers come from.

They come from one specific arm of one specific trial, AREDS2, in one specific population. Knowing that is the difference between citing evidence and copying a competitor’s panel.

And the honest consequence of knowing it: the evidence is narrower than the way these products are marketed.

This is information, not medical advice. Macular degeneration is diagnosed and monitored by an eye specialist, and supplementation in that condition is their decision.

What these two actually are

Lutein and zeaxanthin are xanthophyll carotenoids, the yellow pigments in green leafy vegetables, maize and egg yolk.

And the reason they are interesting is not an abstract antioxidant story. It is anatomical.

They physically accumulate in the macula, the small central part of the retina responsible for detailed vision, at concentrations far above those anywhere else in the body. That deposit is called the macular pigment, and it is literally yellow, which is why the macula is also called the macula lutea, the yellow spot.

Meso-zeaxanthin, a third member, is found in the macula and is largely converted there from lutein rather than obtained from food. Some formulations add it; the independent evidence for doing so is thinner than the marketing suggests.

And the distribution within the macula is specific: zeaxanthin and meso-zeaxanthin are concentrated at the very centre, lutein more towards the periphery. This is the basis for including both rather than one, and it is a genuinely good reason, unlike most ingredient-stacking.

The two proposed mechanisms

Both are plausible and both are physical rather than vague.

1. Blue light filtering. Macular pigment absorbs short-wavelength blue light, which is the most energetic part of visible light reaching the retina. It sits in front of the photoreceptors, so it acts as an internal filter.

2. Antioxidant protection. The retina is unusually vulnerable to oxidative damage, it has high oxygen consumption, high polyunsaturated fat content in photoreceptor membranes, and constant light exposure. These carotenoids quench reactive oxygen species there.

And there is a measurable marker: macular pigment optical density (MPOD), which can be measured and does rise with supplementation. That is a real, demonstrable effect, the substance gets where it is supposed to go.

What is less clear is what that measurable rise does for vision in a healthy eye.

Where the numbers come from

This is the part worth getting right.

AREDS (the original Age-Related Eye Disease Study) tested a formulation of vitamin C, vitamin E, beta-carotene and zinc with copper in people with age-related macular degeneration. It found a reduction in progression to advanced AMD in those with intermediate AMD or advanced disease in one eye.

AREDS2 then tested variations, and two findings matter:

First, substituting lutein 10 mg and zeaxanthin 2 mg for beta-carotene performed at least as well, and beta-carotene had a specific problem (below). The combined analysis suggested a modest benefit from the lutein/zeaxanthin substitution, particularly in participants whose dietary intake of these carotenoids was lowest.

Second, adding omega-3 (EPA and DHA) produced no additional benefit, a negative finding that is routinely ignored by products marketing omega-3 for eyes on AREDS’s reputation.

So the 10:2 ratio is simply the dose used in that trial arm. It is not a biologically optimised ratio, and it is not a ratio found in the macula or in food. It is a trial dose that became an industry standard.

That is worth saying plainly, because formulators cite it as though it were a physiological constant.

The beta-carotene problem, and why it matters commercially

The original AREDS formula contained beta-carotene.

And beta-carotene supplementation has been associated with an increased risk of lung cancer in smokers and former smokers, in large trials in other contexts.

That is why AREDS2 replaced it with lutein and zeaxanthin, and why a smoker or former smoker should not take a beta-carotene-containing eye formula.

For a formulator this is not a footnote. It is a safety requirement: if you make an AREDS-type product, use the AREDS2 composition, not the original. Beta-carotene-containing eye formulas are still sold in India, and they should not be.

Where the evidence stops, honestly

This is the section that works against our own category.

Established: in people with intermediate or advanced AMD, the AREDS2 formulation reduces the rate of progression. This is good evidence from a large, well-conducted randomised trial.

Not established:

Prevention of AMD in healthy eyes. AREDS did not show that the formulation prevents AMD from developing in people who did not already have it. This is the single most important limit, and it is the one that eye supplement marketing ignores entirely.

Early AMD. The benefit was in intermediate and advanced stages, not the earliest.

Cataract. AREDS2 did not find a significant effect on cataract progression.

Improving vision. These do not sharpen eyesight. They slow progression of a specific disease.

Refractive error. Nothing here changes your spectacle number.

Screen use and “blue light protection”. This is where the market has run furthest ahead of the data. The blue-light filtering mechanism is real; the claim that supplementing protects against screen exposure, or relieves digital eye strain, rests on small, short, often industry-funded studies with soft outcomes. And the broader premise is itself shaky, the evidence that screen blue light damages the retina at real-world exposure levels is weak. Screen discomfort is substantially a dry eye and blink-rate problem.

Honest summary: a real anatomical mechanism, a measurable marker, solid evidence in one specific disease stage, and a large marketing structure built on top of ground the evidence does not cover.

Food first, and here it genuinely applies

Unlike some nutrients, the dietary sources are good and abundant in India.

The richest sources:

Dark green leafy vegetables, and palak (spinach), methi, bathua, chaulai, sarson and drumstick (moringa) leaves are all substantial. Kale is the usual Western example; palak and moringa do the same job here.

Egg yolk, and this is worth a specific note: egg yolk has a much lower absolute content than greens, but its bioavailability is considerably higher because the carotenoids come packaged with fat. Two eggs may deliver as much absorbed lutein as a larger serving of greens.

Maize (corn), a notable zeaxanthin source.

Also: capsicum (especially orange and yellow), peas, broccoli, pumpkin, papaya, mango, orange, and marigold-derived colourants.

And three things that determine whether you absorb them:

Fat. These are fat-soluble. Greens cooked with oil or ghee, or eaten with curd or nuts, deliver far more than greens eaten fat-free. This is the most useful practical point here, and it is why a fat-free “healthy” salad is a poor vehicle.

Light cooking helps, it breaks the plant matrix and improves release. Prolonged cooking destroys. Lightly sautéed beats both raw and boiled-to-death.

Chopping and blending also improve release.

So: palak sautéed in a little oil, with curd on the side. That is better formulation advice than most capsules.

Formulating with these, practical notes

For anyone specifying a product.

1. Use the AREDS2 composition if you are making an AREDS-type product, and say so accurately. Do not include beta-carotene.

2. Source and form. Lutein is almost universally extracted from marigold (Tagetes erecta) flowers, which India produces at scale. Check whether the label states free lutein or lutein esters, esters contain less actual lutein by weight and need to be hydrolysed in the gut. A “20 mg lutein esters” claim is not 20 mg of lutein. This is a common and under-scrutinised labelling issue.

3. It needs fat for absorption. A dry powder in a hard capsule absorbs poorly. An oil-suspension softgel, or a formulation taken with food, is materially better, and “take with your largest meal” belongs on the pack.

4. Meso-zeaxanthin is optional. The independent evidence for adding it is limited; it is largely a differentiation play.

5. Omega-3 does not add AREDS benefit. Include DHA if you want its own authorised vision claim, but it has specific intake conditions that the formulation must meet, and it cannot borrow AREDS’s credibility.

6. Zinc and copper together. The AREDS zinc dose is high, and zinc at that level depletes copper, which is exactly why AREDS included copper. A zinc-containing eye formula without copper is a formulation error.

7. Watch the total across your range. A customer taking a multivitamin plus an eye formula may be stacking a high zinc dose.

8. And decide honestly who the product is for. An AREDS-type formula is for people with established AMD, under an ophthalmologist. A general “eye health” product for screen users is a different, weaker proposition, and it should not be dressed in AREDS’s clothes.

Claims, and the specific trap here

What is sayable: vitamin A contributes to the maintenance of normal vision; riboflavin (B2) contributes to the maintenance of normal vision; zinc contributes to the maintenance of normal vision; DHA contributes to the maintenance of normal vision where the product delivers the required daily intake; vitamin C and E contribute to the protection of cells from oxidative stress; copper contributes to normal connective tissue.

And the trap: there is no authorised health claim for lutein or zeaxanthin.

A label cannot make a function claim about them, not “supports macular health”, not “filters blue light”, not “protects the retina”, however real the mechanism and however good the AREDS2 data.

This is a regulatory fact that surprises most formulators, and it is exactly parallel to CoQ10 and L-carnitine in other categories. You can include the ingredient and declare its quantity. You cannot claim what it does.

What is not sayable, in any case: improves eyesight, prevents or treats macular degeneration, prevents cataract, reduces spectacle power, protects against screen damage, or relieves eye strain.

And what we decline: “blue light protection” artwork, which is the dominant positioning in this category and the least supported; any “improves vision” claim; and any product aimed at children’s eyesight.

The honest ranking

If someone asked what to do for their eyes:

1. Have an eye examination. Glaucoma and diabetic retinopathy are silent, and both cause irreversible loss. In diabetes, annually, regardless of symptoms.

2. Control blood sugar and blood pressure, and stop smoking. Smoking is an established risk factor for both AMD and cataract.

3. Children: outdoor time. The evidence on slowing myopia progression is genuinely good.

4. Eat the greens, cooked with some fat, and eggs if you eat them.

5. UV-protective sunglasses.

6. And if you have diagnosed intermediate or advanced AMD, discuss an AREDS2 formulation with your ophthalmologist. This is where a supplement in this category has real, demonstrated value.

For everyone else, including heavy screen users, the honest position is that an eye supplement is a reasonable nutritional addition and not a protective measure. We make one, and that is what we will say about it.

When to see a doctor

Urgently:

• Sudden loss or blurring of vision, even in one eye
• A curtain or shadow across the vision, or a sudden shower of floaters and flashes, possible retinal detachment; hours matter
• Straight lines appearing bent or wavy, possible AMD change
• Severe eye pain with redness, vomiting and haloes around lights, acute glaucoma
• Sudden double vision
• Any eye injury or chemical splash, irrigate with clean water for 15–20 minutes and go immediately

Soon:

• Diabetes and no eye examination in the last year, even with perfect vision
• Over 40 and never screened for glaucoma
• A family history of glaucoma or AMD
• Before starting any eye formula if you smoke or used to, avoid beta-carotene
• Before high-dose zinc, if you take antibiotics or other supplements containing zinc
• Difficulty reading, needing more light, or faded colours
• A child squinting, tilting their head, or dropping behind at school

The short version

1. Lutein and zeaxanthin physically accumulate in the macula, the yellow macular pigment.
2. Zeaxanthin sits at the very centre, lutein more peripherally, a genuine reason to include both.
3. Two plausible, physical mechanisms: blue light filtering and antioxidant protection.
4. Macular pigment density does measurably rise with supplementation.
5. The 10:2 ratio is simply the AREDS2 trial dose, not a biological constant, and not a ratio found in food.
6. AREDS2 substituted them for beta-carotene and performed at least as well.
7. Beta-carotene is associated with raised lung cancer risk in smokers, never use it in an eye formula.
8. AREDS2 found no added benefit from omega-3, which eye marketing ignores.
9. The established benefit is slowing progression in intermediate or advanced AMD.
10. Prevention in healthy eyes was not shown. This is the limit the market ignores.
11. No significant effect on cataract progression.
12. These do not sharpen vision or change spectacle power.
13. The “blue light protection” claim is the least supported and the most marketed.
14. Dietary sources are abundant in India, palak, methi, bathua, sarson, moringa leaves, maize.
15. Egg yolk is lower in content and much higher in bioavailability.
16. They need fat to be absorbed, greens with oil, ghee, curd or nuts.
17. Light cooking improves release; prolonged cooking destroys.
18. Lutein esters are not the same weight as free lutein. Check the label.
19. A dry powder capsule absorbs poorly, oil suspension, or take with the largest meal.
20. Meso-zeaxanthin is largely a differentiation play.
21. Zinc at AREDS doses depletes copper, which is why AREDS included copper.
22. There is no authorised health claim for lutein or zeaxanthin. You can declare them; you cannot claim what they do.
23. An eye examination does more than any supplement, glaucoma and diabetic retinopathy are silent.
24. In diabetes: annual eye examination, whatever the vision.

Composition detail: Optimo 360 and moringa powder. Related: आँखों की रोशनी बढ़ाने के उपाय, triphala for eyes, the classical use, and the 20-20-20 rule and other screen habits.